Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $106M | $13.4M | $31.5M | $26.9M | $55.8M | $70.4M | $94.6M | $7.53M | $18.5M | $88.0M |
| Revenue growth | — | -87.4% | 135.6% | -14.7% | 107.8% | 26.2% | 34.3% | -92.0% | 145.3% | 376.6% |
| Operating income | $18.7M | -$113M | -$88.9M | -$98.9M | -$93.9M | -$186M | -$324M | -$496M | -$536M | -$612M |
| Operating margin | 17.6% | -848.3% | -282.3% | -368.0% | -168.3% | -264.5% | -342.8% | -6589.7% | -2902.7% | -695.4% |
| Net income | $16.5M | -$128M | -$106M | -$122M | -$127M | -$215M | -$389M | -$526M | -$590M | -$785M |
| Net margin | 15.5% | -955.9% | -337.4% | -452.9% | -228.0% | -305.7% | -411.2% | -6988.6% | -3191.1% | -891.6% |
| EPS (diluted) | $0.39 | -$2.59 | -$1.95 | -$2.11 | -$1.97 | -$2.80 | -$4.33 | -$5.45 | -$5.26 | -$6.54 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $37.0M | -$102M | -$101M | -$90.9M | $8.94M | -$143M | -$300M | -$414M | -$396M | -$510M |
| Capital expenditures | $1.60M | $2.88M | $889K | $2.62M | $11.1M | $48.9M | $11.3M | $1.42M | $3.91M | $24.8M |
| Free cash flow | $35.4M | -$105M | -$102M | -$93.5M | -$2.11M | -$191M | -$311M | -$416M | -$400M | -$535M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $66.9M | $125M | $42.3M | $36.4M | $83.0M | $113M | $65.6M | $113M | $94.9M | $123M |
| Total assets | $170M | $295M | $211M | $290M | $534M | $841M | $1.01B | $824M | $1.40B | $1.42B |
| Total liabilities | $75.8M | $185M | $185M | $301M | $420M | $597M | $1.12B | $1.21B | $1.54B | $2.08B |
| Long-term debt | $27.4M | $31.8M | $39.8M | $45.1M | $46.2M | $47.4M | $63.8M | $58.4M | $93.2M | $246M |
| Shareholders' equity | $94.4M | $110M | $25.9M | -$10.9M | $113M | $244M | -$108M | -$386M | -$135M | -$660M |
| Retained earnings | -$518M | -$646M | -$743M | -$865M | -$992M | -$1.21B | -$1.59B | -$2.11B | -$2.70B | -$3.49B |
| Shares (wtd avg diluted) | 42.6M | 49.4M | 54.7M | 59.2M | 64.5B | 76.9B | 89.8B | 96.5B | 112K | 120K |
Every figure is extracted from CYTOKINETICS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.